Fundraising Fox
Addex Therapeutics
NASDAQ: ADXNGeneva · Founded 2002 · Switzerland corporation · 18 employees on LinkedIn · 4 known investors
Find your way into Addex Therapeutics
Sign up to see every warm intro you have to Addex Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Addex Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Addex Therapeutics is a clinical-stage pharmaceutical company that develops orally available small molecule drugs known as allosteric modulators for neurological disorders.
Founders & leadership
MK
Mikhail KalinichevHead of Translational ScienceMikhail Kalinichev holds a PhD in behavioral neuroscience and has spent over 20 years in pharmaceutical research and development across Europe and North America, with expertise in in vivo pharmacology, translational neuroscience, and CNS disorders; he holds multiple patents related to pain management and neurological conditions.
JR
Jean-Philippe RocherHead of Discovery2018–2024Jean-Philippe Rocher is a medicinal chemist with over 30 years of experience in drug discovery and development at pharmaceutical and biotech companies, including work on allosteric modulation approaches and four new chemical entities that advanced to Phase IIa proof-of-concept studies. He has held scientific and management roles at companies in Europe, the US, and Japan, overseeing chemistry platforms, intellectual property strategy, and research collaborations.
RL
TD
Timothy DyerExecutive
VL
Vincent LawtonNamed on SEC filing
RH
Raymond HillNamed on SEC filing
Board
Investors · 4
New Enterprise Associates (NEA)listed by New Enterprise Associates (NEA)Menlo Park · $200K – $40M
How we know: open dataset · 5k.vc investor directory · Not right? Tell us
Sofinnova Partnerslisted by Sofinnova PartnersParis · $540K – $27M
How we know: Sofinnova Partners's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$13.9M disclosed across 3 rounds · 2021–2023
▶$3.7MraisedApr 2023 · 1 investors · BiotechnologyRule 506(b)
▶$3.7MraisedApr 2023 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jean-Philippe RocherExecutive Officer
- Vincent LawtonDirector
- Mikhail KalinichevExecutive Officer
- Jake NunnDirector
- Timothy DyerExecutive Officer, Director
- Isaac MankeDirector
- Robert LutjensExecutive Officer
- Raymond HillDirector
- Roger MillsExecutive Officer, Director
- Offering amount
- $3.7M
- Amount sold
- $3.7M
- First sale
- Apr 2023
- Incorporated
- Corporation, Switzerland
- Federal exemptions
- 06b
▶$4.2MraisedAug 2022 · 1 investors · BiotechnologyRule 506(b)
▶$4.2MraisedAug 2022 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Roger MillsExecutive Officer, Director
- Mikhail KalinichevExecutive Officer
- Isaac MankeDirector
- Jean-Philippe RocherExecutive Officer
- Vincent LawtonDirector
- Jake NunnDirector
- Raymond HillDirector
- Robert LutjensExecutive Officer
- Timothy DyerExecutive Officer, Director
- Offering amount
- $4.2M
- Amount sold
- $4.2M
- Sales commissions
- $285.6K
- Placement agents
- H.C. Wainwright & Co., LLC
- First sale
- Jul 2022
- Incorporated
- Corporation, Switzerland
- Federal exemptions
- 06b
▶$5.9MraisedDec 2021 · 1 investors · BiotechnologyRule 506(b)
▶$5.9MraisedDec 2021 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Robert LutjensExecutive Officer
- Raymond HillDirector
- Roger MillsExecutive Officer, Director
- Mikhail KalinichevExecutive Officer
- Jake NunnDirector
- Jean-Philippe RocherExecutive Officer
- Timothy DyerExecutive Officer, Director
- Isaac MankeDirector
- Vincent LawtonDirector
- Offering amount
- $5.9M
- Amount sold
- $5.9M
- Sales commissions
- $400.6K
- Placement agents
- H.C. Wainwright & Co., LLC
- First sale
- Dec 2021
- Incorporated
- Corporation, Switzerland
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 5
Adcentrx TherapeuticsAdcentrx Therapeutics is a biotech company focused on the discovery and clinical development of antibody-drug conjugates (ADCs) for oncology. It develops site-specific ADC therapeutics and supporting platform technology for cancer treatment.
Celldex Therapeutics, Inc.Celldex is a biotechnology company developing therapeutics across therapeutic areas including immunology and inflammation. The page shown is a board director biography rather than a company overview.
BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
ADARx PharmaceuticalsADARx is a clinical-stage biotechnology company developing RNA-targeted therapeutics designed to control the expression of disease-driving genes. It focuses on treatments for a range of diseases with unmet medical needs.
ExelixisExelixis is an oncology company that discovers and develops cancer treatments, including small molecule therapeutics and biotherapeutics such as antibody-drug conjugates, for patients across multiple tumor types. Its flagship commercial product is CABOMETYX (cabozantinib), and it operates through global development and commercialization partnerships.
Companies working in the same space as Addex Therapeutics.
In the news
Frequently asked questions
- What does Addex Therapeutics do?
- Addex Therapeutics is a clinical-stage pharmaceutical company that develops orally available small molecule drugs known as allosteric modulators for neurological disorders.
- Who are Addex Therapeutics's investors?
- Addex Therapeutics's investors include New Enterprise Associates (NEA), Sofinnova Partners, ACORN BIOVENTURES, SR One Capital Management.
- How much funding has Addex Therapeutics raised?
- Addex Therapeutics has disclosed $13.9M raised across 3 rounds.
- Where is Addex Therapeutics headquartered?
- Addex Therapeutics is headquartered in Geneva.